Addex Therapeutics Launches Neurosterix for Treating Neurological Disorders
Wednesday, 3 April 2024, 13:03
Addex Therapeutics Launches Neurosterix
Addex Therapeutics has announced the launch of Neurosterix, a new company targeting the treatment of neurological disorders. The company has secured an initial funding of $63M to support its innovative endeavors. This move has resulted in a 14% premarket increase in Addex Therapeutics shares, reflecting positive market sentiment towards the potential of Neurosterix.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.